BeckerM, SchumacherN, SchmidtE, et al.Evaluation and comparison of clinical and iLaboratory characteristics of patients with IgA epidermolysis bullosa acquisita, linear IgA bullous dermatosis, and IgG epidermolysis bullosa acquisita. JAMA Dermatol, 2021; 157(8):917–923.
2.
ValeECSD, DimatosOC, PorroAM, et al.Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis—Brazilian Society of Dermatology. An Bras Dermatol, 2019; 94(2 Suppl 1):48–55.
3.
StroberB, BuonannoM, ClarkJD, et al.Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol, 2013; 169(5):992–999.
4.
HashizumeM, HiguchiY, UchiyamaY, et al.IL-6 plays an essential role in neutrophilia under inflammation. Cytokine, 2011; 54(1):92–99.
5.
TakatsuK, NakajimaH.IL-5 and eosinophilia. Curr Opin Immunol, 2008; 20(3):288–294.
